Selected studies of daratumumab in patients with relapsed/refractory AL amyloidosis
| Study . | N . | Prospective/ retrospective . | Response (%) . | CR (or ≥VGPR) (%) . | OS/EF or PFS . |
|---|---|---|---|---|---|
| Abeykoon et al26 | 44 | R | 88 | 17 | OS NA EFS 15 mo |
| Chung et al28 | 72 | R | 77 | 40 | At 2 y: OS, 86%; TTNT not reached, 62% |
| Van de Wyngaert et al29 | 15 | R | 86 | 43 | OS, 87% at 8 mo |
| Milani et al30 | 72 | R | 82 | 15 | NA |
| Kimmich et al31 | 106 | R | 64 | ≥VGPR 48 | OS, 25 mo EFS, 11 mo |
| Lecumberri et al32 | 38 | R | 72 | 28 | At 12 mo: OS, 59% EFS, 52% |
| Sanchorawala et al33 | 22 | P | 90 | 41 | PSF, 20 mo |
| Roussel et al37 | 40 | P | 55 | 15 | At 2 y OS, 74% |
| Cohen et al35 | 50 | R | 84 | 38 | OS, NR PFS, NR |
| Lee et al27 | 10 | R | 90 | 20 | NA |
| Shragai et al36 | 49 | R | 81 | ≥VGPR 64 | OS, NR PFS, 28 mo |
| Szalat et al34 | 107 | R | 93 | 44 | OS, NR MOD-PFS, 36 mo |
| Study . | N . | Prospective/ retrospective . | Response (%) . | CR (or ≥VGPR) (%) . | OS/EF or PFS . |
|---|---|---|---|---|---|
| Abeykoon et al26 | 44 | R | 88 | 17 | OS NA EFS 15 mo |
| Chung et al28 | 72 | R | 77 | 40 | At 2 y: OS, 86%; TTNT not reached, 62% |
| Van de Wyngaert et al29 | 15 | R | 86 | 43 | OS, 87% at 8 mo |
| Milani et al30 | 72 | R | 82 | 15 | NA |
| Kimmich et al31 | 106 | R | 64 | ≥VGPR 48 | OS, 25 mo EFS, 11 mo |
| Lecumberri et al32 | 38 | R | 72 | 28 | At 12 mo: OS, 59% EFS, 52% |
| Sanchorawala et al33 | 22 | P | 90 | 41 | PSF, 20 mo |
| Roussel et al37 | 40 | P | 55 | 15 | At 2 y OS, 74% |
| Cohen et al35 | 50 | R | 84 | 38 | OS, NR PFS, NR |
| Lee et al27 | 10 | R | 90 | 20 | NA |
| Shragai et al36 | 49 | R | 81 | ≥VGPR 64 | OS, NR PFS, 28 mo |
| Szalat et al34 | 107 | R | 93 | 44 | OS, NR MOD-PFS, 36 mo |
NA, not applicable; NR, not reached; P, prospective; R, retrospective; TTNT, time to next treatment.